DIEX Recherche Sherbrooke, Inc

Summary

DIEX Recherche Sherbrooke, Inc is a medical facility located in SHERBROOKE, Quebec. This center is recognized for care of Alzheimer's Disease, Atopic Dermatitis, Psoriasis, Type 2 Diabetes, Chronic Cough and other specialties. DIEX Recherche Sherbrooke, Inc is involved with conducting 87 clinical trials across 123 conditions. There are 3 research doctors associated with this hospital, such as Marcel Germain, Marylene Dussault, and Daniel Minier.

Top PIs

Clinical Trials running at DIEX Recherche Sherbrooke, Inc

Crohn's Disease

Type 2 Diabetes

Bullous Pemphigoid

Antiphospholipid Syndrome

Thrombocytopenic Purpura

Hidradenitis Suppurativa

Systemic Lupus Erythematosus

Cutaneous Lupus Erythematosus

Inflammatory Bowel Disease

Diabetes

Tulisokibart

for Crohn's Disease

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

Recruiting

1 award

Phase 3

1 criteria

Targeted Therapies

for Crohn's Disease

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, ABBV-382 and lutikizumab. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 500 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and ABBV-382 are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. Each group includes a 12-week induction period, a 12-week maintenance period, and an optional long-term extension period where medication will be given after the maintenance period. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.

Recruiting

1 award

Phase 2

1 criteria

MORF-057

for Crohn's Disease

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

Recruiting

0 awards

Phase 2